Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Common Equity: 2009-2024

Historic Common Equity for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to $538.5 million.

  • Vanda Pharmaceuticals' Common Equity fell 13.90% to $466.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $466.0 million, marking a year-over-year decrease of 13.90%. This contributed to the annual value of $538.5 million for FY2024, which is 1.17% down from last year.
  • Vanda Pharmaceuticals' Common Equity amounted to $538.5 million in FY2024, which was down 1.17% from $544.9 million recorded in FY2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Common Equity peaked at $544.9 million during FY2023, and registered a low of $453.3 million during FY2020.
  • For the 3-year period, Vanda Pharmaceuticals' Common Equity averaged around $536.9 million, with its median value being $538.5 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first increased by 11.40% in 2021, then dropped by 1.17% in 2024.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Common Equity stood at $453.3 million in 2020, then increased by 11.40% to $504.9 million in 2021, then rose by 4.41% to $527.2 million in 2022, then increased by 3.36% to $544.9 million in 2023, then decreased by 1.17% to $538.5 million in 2024.